Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Jul;29(4):398-9.
doi: 10.1111/pcmr.12473. Epub 2016 May 17.

Using avatars to win the fight over BRAF inhibitor resistance

Anna E Vilgelm, Ann Richmond  1
Affiliations
Comment

Using avatars to win the fight over BRAF inhibitor resistance

Anna E Vilgelm et al. Pigment Cell Melanoma Res. 2016 Jul.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Strategy for the selection of second line therapy proposed by Krepler et al. Tumor tissue from melanoma patients that relapsed on BRAF inhibitor therapy is implanted into immunodeficient mice for expansion. Resulting patient-derived xenograft tumors are subjected to genomic and proteomic analysis to gain information on the targetable mechaisms of BRAF inhibitor resistanse that is then used to design personalized pre-clinical trial of potential second line therapies using PDX-bearing mice. Mut. - mutated, ampl. - amplified, activ. - activated.
See this image and copyright information in PMC

Comment on

References

    1. Gao H, Korn JM, Ferretti S et al. (2015). High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 21, 1318–1325. - PubMed
    1. Hidalgo M, Amant F, Biankin AV et al. (2014). Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 4, 998–1013. - PMC - PubMed
    1. Vilgelm AE, Pawlikowski JS, Liu Y et al. (2015). Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Cancer Res. 75, 181–193. - PMC - PubMed
    1. Vilgelm AE, Johnson CA, Prasad N et al. (2016). Connecting the dots: therapy-induced senescence and a tumor-suppressive immune microenvironment. J. NatlCancer Inst. 108. - PMC - PubMed